Vertex Pharmaceuticals saw a notable 20.53% share price increase over the last quarter, which coincided with several key developments in its Type 1 Diabetes (T1D) initiatives. The company ...

We feel now is a pretty good time to analyse Vertex, Inc.'s (NASDAQ:VERX) business as it appears the company may be on the cusp of a considerable accomplishment. Vertex, Inc., together with its ...

We feel now is a pretty good time to analyse Vertex, Inc.'s (NASDAQ:VERX) business as it appears the company may be on the cusp of a considerable accomplishment. Vertex, Inc., together with its ...

In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other most expensive stocks insiders are dumping in March. After being in the ...

Vertex Pharmaceuticals (VRTX) closed the latest trading day at $492.69, indicating a -1.96% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily ...

We recently published a list of 20 Most Expensive Stocks Insiders Are Dumping In March. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands ...

The reason behind the shape of manhole covers have been revealed.

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

The Global 3D Cell Culture Market is expected to witness a double-digit growth rate by 2027. Some of the key factors driving ...